While a phase 1 trial (NCT03413319) in PSP patients showed safety and good tolerability (Sandusky-Beltran and Sigurdsson, 2020), interim results of a phase 2 trial (NCT02985879) in patients with PSP symptoms for <5 years failed to find any therapeutic beneficial effects of this antibody (Alzforum.org, News, https://www.alzforum.org/news/research-news/abbvies-tau-antibody-flops-progressive-supranuclear-palsy), leading to a discontinuation of the PSP trial (Sandusky-Beltran and Sigurdsson, 2020). The gene discussed is MAPT; the disease is Classical progressive supranuclear palsy.